ALA reduces the risk of cardiovascular disease risk, possibly by favorably modifying vascular inflammation, with reduced levels of CRP, vascular cell adhesion molecule-1 (VCAM-1), E-selectin, serum total cholesterol, LDL and triglyceride levels. This evidence concerns the gene VCAM1 and cardiovascular disorder.